Puma Biotechnology Inc (PBYI)

47.25
NYSE : Health Care
Prev Close 47.25
Day Low/High 0.00 / 0.00
52 Wk Low/High 19.74 / 107.49
Avg Volume 760.70K
Exchange NYSE
Shares Outstanding 32.49M
Market Cap 1.48B
EPS -7.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has submitted a New Drug Application (NDA) to the U.

Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine

Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the positive results from the I-SPY 2 Phase II clinical trial of neratinib for the neoadjuvant treatment of breast cancer were published in...

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

'Mad Money' Lightning Round: I Like Sirius XM Radio

'Mad Money' Lightning Round: I Like Sirius XM Radio

Cramer is taking Southwest Airlines over United Continental while Palo Alto Networks is good value but not great.

Jim Cramer's 'Mad Money' Recap: Add These 2 Stocks to FANG

Jim Cramer's 'Mad Money' Recap: Add These 2 Stocks to FANG

Three of Cramer's four FANG stocks still perform but the fourth can easily be replaced by these two companies.

Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe

Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for neratinib.

August 19th Options Now Available For Puma Biotechnology (PBYI)

August 19th Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the August 19th expiration.

Short Interest Increases 11.8% For PBYI

Short Interest Increases 11.8% For PBYI

The most recent short interest data has been released for the 05/31/2016 settlement date, which shows a 530,564 share increase in total short interest for Puma Biotechnology, Inc. , to 5,028,719, an increase of 11.80% since 05/13/2016.

Puma Biotechnology Presents Positive Phase II Data At The 2016 ASCO Annual Meeting

Puma Biotechnology Presents Positive Phase II Data At The 2016 ASCO Annual Meeting

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator-sponsored Phase II trial of neratinib with HER2-mutated, non-amplified breast cancer.

Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting

Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO)...

Puma Biotechnology To Present At UBS Global Healthcare Conference

Puma Biotechnology To Present At UBS Global Healthcare Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

July 1st Options Now Available For Puma Biotechnology (PBYI)

July 1st Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the July 1st expiration.

Puma Biotechnology Reports First Quarter 2016 Financial Results

Puma Biotechnology Reports First Quarter 2016 Financial Results

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2016.

Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference

Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016

Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that its drug candidate neratinib was highlighted in three poster presentations at the American Association for Cancer Research (AACR) Annual...

Puma Biotechnology's NEfERT-T Phase II Study Published Online In JAMA Oncology

Puma Biotechnology's NEfERT-T Phase II Study Published Online In JAMA Oncology

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from the NEfERT-T Phase II clinical trial of neratinib in ERBB2-positive metastatic breast cancer patients were published online in...

Puma Biotechnology (PBYI) Stock Plunges on Delayed Marketing Application

Puma Biotechnology (PBYI) Stock Plunges on Delayed Marketing Application

Puma Biotechnology (PBYI) stock is lower in early-morning trading on Tuesday after the company announced that it will delay filing its New Drug Application (NDA) for a breast cancer drug.

Puma Biotechnology Updates Timeline For Filing New Drug Application

Puma Biotechnology Updates Timeline For Filing New Drug Application

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that based on its recent meetings with the U.

Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016

Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting 2016.

Puma Biotechnology To Present At Cowen's Health Care Conference

Puma Biotechnology To Present At Cowen's Health Care Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Reports Fourth Quarter And Full Year 2015 Financial Results

Puma Biotechnology Reports Fourth Quarter And Full Year 2015 Financial Results

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2015.

Puma Biotechnology To Participate In Fireside Chat At RBC Capital Markets Global Healthcare Conference

Puma Biotechnology To Participate In Fireside Chat At RBC Capital Markets Global Healthcare Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Announces The Conclusion And Final Results Of Eshelman's Consent Solicitation

Puma Biotechnology Announces The Conclusion And Final Results Of Eshelman's Consent Solicitation

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the deadline for Fredric Eshelman to deliver the requisite consents expired on February 15, 2016, and that Puma's shareholders have...

Puma Biotechnology's ExteNET Phase III Study Published Online In The Lancet Oncology

Puma Biotechnology's ExteNET Phase III Study Published Online In The Lancet Oncology

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from the ExteNET Phase III clinical trial of neratinib in patients with early stage HER2 positive breast cancer were published in...

Puma Biotechnology To Participate In Fireside Chat At Leerink Partners Global Healthcare Conference

Puma Biotechnology To Participate In Fireside Chat At Leerink Partners Global Healthcare Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

Interesting PBYI Put And Call Options For September 16th

Interesting PBYI Put And Call Options For September 16th

Investors in Puma Biotechnology, Inc. saw new options become available this week, for the September 16th expiration.

Puma Biotechnology Stock Sees Short Interest Make 46% Move

Puma Biotechnology Stock Sees Short Interest Make 46% Move

The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 2,003,507 share increase in total short interest for Puma Biotechnology, Inc. , to 6,371,236, an increase of 45.87% since 12/15/2015.

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

I'm only making one big prediction this year: The five-year party which saw biotech stocks outperform the broader markets comes to an end in 2016.